Frenquel, a Blocking Agent Against Experimental LSD‐25 and Mescaline Psychosis
Neurology May 1, 1955 Howard D. Fabing 41 citations
A combination of dextromethorphan and quinidine (AVP-923) reduces pseudobulbar affect—uncontrollable episodes of laughing or crying—in people with amyotrophic lateral sclerosis (ALS). In a 28-day trial, patients taking the combination showed a 3.3-point greater improvement on a lability scale compared with dextromethorphan alone and a 3.7-point greater improvement compared with quinidine alone. They also had fewer episodes overall and better quality-of-life and relationship scores. Adverse effects were mostly mild or moderate; 24% of those on the combination discontinued treatment due to side effects, versus 6% and 8% for the individual components.